Synaptogenix Inc (SNPX)

[SF Wolf]

Lane Simonian, the author of the article in question while well intentioned, is not a scientist or researcher he is a history teacher.

He states:

“Bryostatin by Neurotrope (OTCQB:NTRPD) downregulates protein kinase C alpha and protein kinase C alpha is the linchpin in the initial production of inflammation and oxidation in Alzheimer's disease (bryostatin's effect, protein kinase C alpha). However, due to damage to upstream receptors in most people with Alzheimer's disease, protein kinase C alpha activity decreases as the disease progresses (study). So it is not likely that bryostatin can be used to help most people at least not past a certain stage.”

His statement is not backed up by any reference citing research to prove his point. It is clearly only his opinion and not in any way reflects scientific thought into the multi modal effects of Byrostatin.
http://seekingalpha.com/article/4054680-alzheimers-disease-next

I would rather listen to the principal researcher in the field, Dr. Alkon:

My notes from Dr. Alkon’s BIO CEO presentation 02/13/17:

Minute 17:54: I do want to say that Bryostatin is one of a platform of drugs that we have. It is our lead compound now because it has experience in the patient population and we know it’s well tolerated. But we have 40 or so other compounds some of which are even more potent and even more specific and have proprietary composition of matter protection which we can use for second and third generation of drugs.

Minute 23: (Bryostatin) is well positioned to virtually…take care of every major aspect of this disease. So it is multi modal, multi modal means that we can look at prevention, slowing down progression, and actual reversal of Alzheimer’s disease. Which is what is in our current Phase 2 trial.

Minute 25:45 (refer to Slide 40 – Bryostaten Compassionate Use Program: Severe Alzheimer’s Disease “No other reports have ever shown comparable benefits in such severely demented patients”) These are our compassionate use patients…we saw major reversal of disease that’s why we teed-up our Phase 2 trial in the way we did for severe (Alzheimer’s) patients to see reversal. To see not just a reduction in the rate of decline…but a flipping, a changing of the sign of what happens, for example, with the preferred metric of advanced Alzheimer’s disease, the Severe Impairment Battery.

https://www.veracast.com/webcasts/bio/ceoinvestor2017/18111483071.cfm